GlassScriptPhysician profile
Salvador Lopez
NPI 1649726852
$17,086.30
in general payments reported to CMS, 2019-2025
39 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,433 · 2022: $2,453 · 2023: $7,261 · 2024: $2,364 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,695 · Travel and Lodging: $5,350 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,695.12 |
| Travel and Lodging | $5,349.81 |
| Education | $154.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,349.81 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $2,792.75 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,588.96 | 2021-2025 | |
| Pfizer INC. | $946.50 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.58 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $605.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $511.21 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $443.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $441.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $416.10 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $380.30 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $372.53 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $282.71 | 2021-2022 | |
| Mylan Specialty L.P. | $215.92 | 2021-2024 | Yupelri, Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $186.98 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $180.97 | 2023-2024 | Rexulti |
| Amgen INC. | $173.87 | 2021-2024 | Repatha, Otezla |
| Lundbeck LLC | $146.77 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $139.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $137.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.50 | 2021-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $125.34 | 2022-2025 | Injectafer |
| Exact Sciences Corporation | $124.01 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $122.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.51 | 2022-2024 | |
| Corcept Therapeutics | $81.24 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $65.22 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $60.62 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $44.58 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $37.26 | 2021 | |
| Indivior INC. | $34.86 | 2021-2022 | |
| Gilead Sciences, INC. | $30.61 | 2025 | |
| Vanda Pharmaceuticals INC. | $30.34 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $27.17 | 2025 | M-M-R II, Varivax, Capvaxive |
| Eisai INC. | $22.21 | 2021 | |
| Viatris Specialty LLC | $20.33 | 2025 | Yupelri |
| Medtronic, INC. | $19.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.67 | 2022 | |
| Alkermes, INC. | $16.55 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvador Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.